In this issue:
LA and preserving walking speed plus reducing brain atrophy
Age onset and MG characteristics
Impact of spinal cord LME in MOGAD
Prevalence of MDs in antibody-associated neurologic diseases
Origins and disease-relevant mechanisms of autoantibodies in MOGAD
Relapse rates and CASPR2
Prognostic factors for GFAP-A
Efficacy of MRI lesion distribution criteria
OCT changes in MS patients treated with OMB
Cognitive function and relative risks for cognitive impairment with MOGAD
Please login below to download this issue (PDF)